Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition

Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition

Sorafenib, a pan-protein kinase inhibitor, inhibits the activity of various kinases (like vascular endothelial growth factor, platelet-derived growth factor, and rapidly accelerated fibrosarcoma) and clinically has been used to treat different human cancers. This study investigated its antitumor act...

Full description

Bibliographic Details
Main Authors: Tian Chuntao, Liu Ying, Xue Lingfei, Zhang Dong, Zhang Xiaotong, Su Jing, Chen Jiaohong, Li Xiangke, Wang Liuxing, Jiao Shunchang
Format: Article
Language:English
Published: De Gruyter 2022-06-01
Series:Open Life Sciences
Subjects:
ovarian cancer
sorafenib
transforming growth factor-β1
radiosensitivity
Online Access:https://doi.org/10.1515/biol-2022-0066

Internet

https://doi.org/10.1515/biol-2022-0066

Similar Items